课题基金 / 基金详情

Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention

Role of p53 and ptc tumor suppressive pathways in BCCs development and prevention
p53 和 ptc 肿瘤抑制途径在 BCC 发展和预防中的作用
批准号:
7291657
负责人:
Mohammad Athar
金额:
$31.97万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-30 至 2011-05-31
关键词:
AccountingAffectAgeAmericanAnimalsAntineoplastic AgentsApoptosisBasal Cell Nevus SyndromeBasal cell carcinomaBeliefBiologicalBiological AvailabilityBreedingCDKN1A geneCP 31398CalciumCell CycleCell Cycle ArrestCell Cycle RegulationCell NucleusCell ProliferationCellsChemical AgentsChemopreventionChemopreventive AgentChronicClonal ExpansionComplexConditionCyclin D1Cyclin EDNADataDevelopmentDiseaseEMSAEngineeringEpidermisEpithelialErinaceidaeEventFrequenciesG1 ArrestG2/M TransitionGene TargetingGeneticGenetic TranscriptionGrowthHair follicle structureHarvestHot SpotHumanIn complete remissionInbred HRS MiceIncidenceIndividualInduction of ApoptosisInheritedInhibition of ApoptosisKeratinKnowledgeLeadLesionLi-Fraumeni SyndromeLinkMalignant NeoplasmsMediatingMicroscopicMitosisModelingMolecularMolecular ConformationMonitorMorphogenesisMusMutateMutationNF-kappa BNeoplasmsNeoplastic ProcessesNeurologicNewly DiagnosedNumbersOral AdministrationPTCH genePapillomaPathogenesisPathway interactionsPatientsPhenotypePhosphotransferasesPlant RootsPlayPopulationPreventionProliferating Cell Nuclear AntigenProliferation MarkerProteinsProtocols documentationPyrimidine DimersRecruitment ActivityRegulationRegulator GenesRegulatory ElementRegulatory PathwayRhabdomyosarcomaRisk FactorsRoleSamplingSignal PathwaySignal TransductionSkinSkin CancerSkin CarcinogenesisSkin CarcinomaSkin NeoplasmsSquamous cell carcinomaStagingStaining methodStainsSulfasalazineTNFSF10 geneTP53 geneTestingTetracyclineTetracyclinesThinkingTissue SampleTissuesTransfectionTumor Necrosis Factor Ligand Superfamily Member 6Tumor Suppressor GenesTumor TissueUltraviolet B RadiationWestern BlottingXeroderma Pigmentosumanimal databasecarcinogenesiscaspase-3combinatorialcyclin A2cyclin B1cyclopaminegenetic regulatory proteininhibitor/antagonistinsightirradiationkeratinocytemedulloblastomamutantoncoprotein p21pifithrinpreventpromoterresearch studyresponsesurvivintranslational clinical trialtumortumorigenesisultraviolet

项目摘要

项目成果

Mohammad Athar的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):太阳紫外线B(UVB)辐射是诱发和发展包括鳞状细胞癌(SCCs)和基底细胞癌(BCC)在内的非黑色素瘤皮肤癌(NMSC)的主要风险因素,在美国每年有100多万新诊断的人类癌症。UVB导致DNA的结构变化,导致肿瘤抑制基因的热点突变,如BCC中的p53和PTCH,以及这些病变周围的皮损周围皮肤。这些肿瘤的发病机制被认为是由于Sonic Hedgehog(Shh)信号的突变激活和P53的失活,导致细胞凋亡受阻,细胞增殖增强,启动细胞克隆性扩张,从而促进BCC的生长。在这项提议中,我们将检验这样的假设,即shh激活和p53抑制共同驱动BCC的肿瘤过程,并且找到针对UVB对这些信号通路的影响的化学药物将消除这些损伤的发展。在这项研究中,我们将使用基因工程的易患癌症的小鼠模型,模仿易患肿瘤的人类皮肤的表型。其中包括:携带P53+/+P53+/-或P53-/-的ptc1+无毛小鼠;在先前的研究中,我们已经证明携带P53+/+的ptc1+/SKH1无毛小鼠除横纹肌肉瘤外,还会自发发生多个人BCC样病变。慢性UVB照射这些小鼠的皮肤很容易诱发多种肿瘤,包括乳头状瘤、鳞状细胞癌和基底细胞癌,提供了一种独特的相关的人类皮肤癌诱导的小鼠模型。在这个小鼠模型中,我们将研究靶向抗癌药物的作用,包括环多巴胺和CP-31398,它们分别阻断shh激活和将突变的p53转化为功能活性蛋白。我们还将评估核因子kappaB(NFkB)的作用,它也是由UVB辐射皮肤诱导的,通过使用柳氮磺胺吡啶,通过直接抑制IKB激酶来阻断NFkB的激活。使用LC-MS,我们已经证明了环多巴胺和CP-31398或柳氮磺胺吡啶联合给药不会改变单独药物的生物利用度。我们相信,这些研究将形成转化性临床试验的基础,通过这些试验试剂的适当组合,可以证明在根除BCC方面非常有效,并可能为易感人群中NMSCs的化学预防提供一种基于机制的独特有效的方法。
英文摘要
DESCRIPTION (provided by applicant): Solar ultraviolet B (UVB) radiation is the major risk factor for the induction and development of non-melanoma skin cancer (NMSC) including squamous cell carcinoma (SCCs) and basal cell carcinoma (BCCs) which account for more than one million newly diagnosed human cancers annually in the USA. UVB causes structural alterations in DNA leading to hot spot mutations in tumor suppressor genes such as p53 and ptch in BCCs and in the perilesional skin surrounding these lesions. The pathogenesis of these tumors is thought to be driven by mutational activation of sonic hedgehog (shh) signaling and inactivation of p53 resulting in blockade of apoptosis and augmentation of cell proliferation and clonal expansion of initiated cells prompting the growth of BCCs. In this proposal we will test the hypothesis that the combination of shh activation and p53 inhibition drives the neoplastic process in BCCs and that finding chemical agents targeted to blocking the effects of UVB on these signaling pathways will abrogate the development of these lesions. For this study we will employ genetically engineered cancer-susceptible murine models that mimic the phenotype of tumor-susceptible human skin. These include: ptc1+ hairless mice carrying p53+/+p53+/- or p53-/-; in prior studies we have shown that ptc1+/SKH1 hairless mice carrying p53+/+ spontaneously develop multiple human BCCs-like lesions in addition to rhabdomyosarcomas. Chronic UVB irradiation of the skin of these mice readily induces multiple tumors including papillomas, SCCs and BCCs, providing a uniquely relevant murine model of human skin cancer induction. In this murine model we will investigate effects of targeted anti-cancer agents including cyclopamine and CP-31398, which block shh activation and convert mutant p53 into a functionally active protein respectively. We will also assess the role of nuclear factor kappa B (NFkB), which is also induced by UVB irradiation of the skin, by using sulfasalazine that blocks NFkB activation by directly inhibiting IkB kinases. Employing LC-MS, we have shown that co-administration of cyclopamine and CP-31398 or sulfasalazine does not alter individual agent's bioavailability. It is our belief that these studies will form the basis for translational clinical trials whereby a suitable combination of these test agents could prove highly effective in abrogating BCCs and may provide a mechanism-based uniquely effective approach for the chemoprevention of NMSCs in susceptible human populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
海外基金